Want to join the conversation?
$GILD, which owns products like Stribild, Atripla and Truvad, said that total 2Q16 revenues were $7.8Bil vs. $8.2Bil in 2Q15. Product sales were $7.7Bil, down 6% vs. 2Q15. The YoverY decline was driven by lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. US product sales were $4.9Bil, down 12% YoverY.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.